-
Abstract Number: 0495
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
-
Abstract Number: 0496
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
-
Abstract Number: 0497
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
-
Abstract Number: 0498
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
-
Abstract Number: 0499
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
-
Abstract Number: 0500
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
-
Abstract Number: 0501
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
-
Abstract Number: 0502
Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
-
Abstract Number: 0503
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
-
Abstract Number: 0504
Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database
-
Abstract Number: 0505
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
-
Abstract Number: 0506
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
-
Abstract Number: 0507
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
-
Abstract Number: 0508
Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
-
Abstract Number: 0509
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 181
- Next Page »